Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial - Bertini, E; Dessaud, E; Mercuri, E; Muntoni, F; Kirschner, J; Reid, C; Lusakowska, A; Comi, GP; Cuisset, JM; Abitbol, JL; Scherrer, B; Ducray, PS; Buchbjerg, J; Vianna, E; van der Pol, WL; Vuillerot, C; Blaettler, T; Fontoura, P; Olesoxime SMA Phase 2 Study Investigators (Lancet Neurol, 2017)